# Anthracycline payloads

Source: https://onco.cc/terms/anthracycline-payloads/  
OnCo record `anthracycline-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Antibodies can carry potent relatives of an established chemotherapy family called anthracyclines. Researchers are testing these payloads as another way to kill targeted cancer cells.

## Summary

PNU-159682 is an anthracycline derivative used in experimental antibody conjugates. A primary study of a uPAR-directed PNU-159682 conjugate reported tumor suppression and changes in the immune environment in pancreatic cancer models. It is a distinct scaffold from camptothecin TOP1 payloads. An anthracycline label alone does not establish the dominant mechanism, resistance profile or clinical safety of each derivative.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: PNU-159682; nemorubicin metabolite payloads; anthracycline antibody conjugates

## Sources

- uPAR-directed anthracycline conjugate in pancreatic cancer models (2025): https://doi.org/10.1126/sciadv.adq0513

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)

---
JSON: https://onco.cc/api/v1/entities/anthracycline-payloads.json